University of North Carolina Lilongwe CRS (12001)
Welcome,         Profile    Billing    Logout  
 2 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hosseinipour, Mina C
HPTN 084, NCT03164564: Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

Active, not recruiting
3
3224
RoW
Oral CAB, Cabotegravir, Oral TDF/FTC, Tenofovir disoproxil fumarate/emtricitabine, Truvada, Placebo for oral CAB, Placebo for oral TDF/FTC, CAB LA, Cabotegravir long-acting injectable, Placebo for CAB LA
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
11/20
11/24
PALISADE, NCT06134362: Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

Recruiting
3
3500
RoW
CAB LA, Apretude, CAB LA for PrEP
ViiV Healthcare, GlaxoSmithKline, PPD DEVELOPMENT, LP
HIV Infections
06/28
06/28
PAUSE, NCT06031272: Pausing Antiretroviral Treatment Under Structured Evaluation

Recruiting
1
48
RoW
3BNC117-LS-J, 10-1074-LS-J, Placebo for 3BNC117-LS-J, Placebo for 10-1074-LS-J
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
06/25
06/26

Download Options